European Commission Approves Second-line Axi-cel for DLBCL/HGBL - OncLive
The European Commission approved axicabtagene ciloleucel (axi-cel; Yescarta) for treating adult patients with DLBCL or HGBL who relapse within 12 months post-first-line chemoimmunotherapy. Based on the ZUMA-7 trial, axi-cel significantly improved event-free survival over standard care, marking a new treatment era. Axi-cel also showed a consistent safety profile and improved quality of life.
Related Clinical Trials
Reference News
The European Commission approved axicabtagene ciloleucel (axi-cel; Yescarta) for treating adult patients with DLBCL or HGBL who relapse within 12 months post-first-line chemoimmunotherapy. Based on the ZUMA-7 trial, axi-cel significantly improved event-free survival over standard care, marking a new treatment era. Axi-cel also showed a consistent safety profile and improved quality of life.